GLP1R and chronic kidney disease: Given the significant unmet need for novel therapeutic interventions in AS, particularly as many patients still progress to KF despite current treatments like RASi, GLP-1 RAs may offer an innovative strategy to delay KF in AS, potentially addressing both metabolic and inflammatory pathways involved in CKD progression [40, 42, 56].